$106 | SAVE $19 | Single User
$213 | SAVE $37 | Site License
$319 | SAVE $56 | Global License

UCB SA - Financial and Strategic SWOT Analysis Review

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review
[Lowest Price Guaranteed: $106]

Published by Global Data: 25 Jul 2018 | 215213 | In Stock
Related Topics: Business , Financial , Psoriasis , Rheumatology

Introduction

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.

- Corporate strategy – Analyst’s summarization of the company’s business strategy.

- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.

- Company history – Progression of key events associated with the company.

- Major products and services – A list of major products, services and brands of the company.

- Key competitors – A list of key competitors to the company.

- Key employees – A list of the key executives of the company.

- Executive biographies – A brief summary of the executives’ employment history.

- Key operational heads – A list of personnel heading key departments/functions.

- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities – A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. UCB is also developing new therapies for neurological and immunological diseases. The company operates subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA Key Recent Developments

Jun 28,2018: New UCB Research Showcases Value of CIMZIA (certolizumab pegol) in Psoriasis and Highlights Unique Experiences and Real World Evidence for Key Patient Populations

Jun 19,2018: Succeeding together UCB joins patients and experts to improve the lives of people with epilepsy[TOPC : Pharma - UCB SA]

Jun 15,2018: New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey

Jun 01,2018: UCB proud to collect Wallonia Export Award

May 22,2018: UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents
for UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

  • Table of Contents

    Table of Contents 3

    List of Tables 5

    List of Figures 5

    Section 1 - About the Company 6

    UCB SA - Key Facts 6

    UCB SA - Key Employees 7

    UCB SA - Key Employee Biographies 8

    UCB SA - Major Products and Services 9

    UCB SA - History 10

    UCB SA - Company Statement 17

    UCB SA - Locations And Subsidiaries 19

    Head Office 19

    Other Locations & Subsidiaries 19

    Joint Venture 22

    Section 2 – Company Analysis 23

    Company Overview 23

    UCB SA - Business Description 24

    UCB SA - Corporate Strategy 25

    UCB SA - SWOT Analysis 26

    SWOT Analysis - Overview 26

    UCB SA - Strengths 26

    UCB SA - Weaknesses 27

    UCB SA - Opportunities 28

    UCB SA - Threats 29

    UCB SA - Key Competitors 30

    Section 3 – Company Financial Ratios 31

    Financial Ratios - Capital Market Ratios 31

    Financial Ratios - Annual Ratios 32

    Performance Chart 35

    Financial Performance 35

    Financial Ratios - Interim Ratios 36

    Financial Ratios - Ratio Charts 37

    Section 4 – Company’s Lifesciences Financial Deals and Alliances 38

    UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 38

    UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 39

    UCB SA, Recent Deals Summary 40

    Section 5 – Company’s Recent Developments 41

    Jun 19, 2018: Succeeding together UCB joins patients and experts to improve the lives of people with epilepsy[TOPC : Pharma - UCB SA] 41

    Jun 15, 2018: New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey 42

    Jun 01, 2018: UCB proud to collect Wallonia Export Award 43

    May 22, 2018: UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority 44

    May 07, 2018: Partnership with Science 37: helping UCB to improve patient experience 45

    May 03, 2018: Science 37 Partners with UCB to Fundamentally Change the Clinical Trial Ecosystem, Focusing on More Patient-Friendly, Technology-Enabled Trials at Home 46

    Apr 23, 2018: Sharing research & supporting development of future neurology leaders at AAN 2018 47

    Mar 22, 2018: CIMZIA Label Update Marks Major Advance For Women Of Childbearing Age With Chronic Inflammatory Disease In U.S. 49

    Mar 21, 2018: GoBoldy: R&D Is An Investment In New Era Of Medicine 50

    Mar 06, 2018: New online tool helps patients and physicians find our clinical studies 51

    Section 6 – Appendix 52

    Methodology 52

    Ratio Definitions 52

    About GlobalData 56

    Contact Us 56

    Disclaimer 56

List Of Tables
in UCB SA - Financial and Strategic SWOT Analysis Review

List of Tables

UCB SA, Key Facts 6

UCB SA, Key Employees 7

UCB SA, Key Employee Biographies 8

UCB SA, Major Products and Services 9

UCB SA, History 10

UCB SA, Subsidiaries 19

UCB SA, Joint Venture 22

UCB SA, Key Competitors 30

UCB SA, Ratios based on current share price 31

UCB SA, Annual Ratios 32

UCB SA, Annual Ratios (Cont...1) 33

UCB SA, Annual Ratios (Cont...2) 34

UCB SA, Interim Ratios 36

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 38

UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 39

UCB SA, Recent Deals Summary 40

Currency Codes 52

Capital Market Ratios 52

Equity Ratios 53

Profitability Ratios 53

Cost Ratios 54

Liquidity Ratios 54

Leverage Ratios 55

Efficiency Ratios 55

List Of Figures, Charts and Diagrams
in UCB SA - Financial and Strategic SWOT Analysis Review

List of Figures

UCB SA, Performance Chart (2013 - 2017) 35

UCB SA, Ratio Charts 37

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 38

UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 39

Additional Details

Publisher

Global Data

Publisher Information

Reference

215213 | GDPH33857FSA

Number of Pages

56

Report Format

PDF

Global Data Reports

This report is published by Global Data

Download Free Report Summary PDF

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...